SMMT
Income statement / Annual
Last year (2023), Summit Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Summit Therapeutics Inc.'s net income was -$614.93 M.
See Summit Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
01/31/2016 |
01/31/2015 |
| Operating Revenue |
$0.00
|
$704,295.00
|
$1.81 M
|
$860,000.00
|
$811,370.00
|
$56.41 M
|
$35.98 M
|
$2.88 M
|
$0.00
|
$2.27 M
|
| Cost of Revenue |
$2.05 M |
$2.51 M |
$0.00 |
$0.00 |
$199,498.00 |
$24,919.00 |
$97,667.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$2.05 M |
-$1.81 M |
$1.81 M |
$860,000.00 |
$611,872.00 |
$56.39 M |
$35.88 M |
$2.88 M |
$0.00 |
$2.27 M |
| Gross Profit Ratio |
0 |
-2.57 |
1 |
1 |
0.75 |
1 |
1 |
1 |
0 |
1 |
| Research and Development
Expenses |
$59.47 M
|
$52.00 M
|
$85.35 M
|
$53.27 M
|
$41.99 M
|
$51.38 M
|
$41.01 M
|
$23.69 M
|
$23.94 M
|
$15.64 M
|
| General & Administrative
Expenses |
$30.27 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$9.29 M
|
$16.19 M
|
$16.98 M
|
$10.35 M
|
$7.45 M
|
$6.80 M
|
| Selling & Marketing
Expenses |
-$2.05 M
|
$0.00
|
$0.00
|
$0.00
|
$2.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.22 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$11.94 M
|
$16.19 M
|
$16.98 M
|
$10.35 M
|
$7.45 M
|
$6.80 M
|
| Other Expenses |
$0.00 |
-$14.42 M |
-$20.97 M |
-$19.31 M |
$0.00 |
-$19.88 M |
-$3.86 M |
-$1.95 M |
-$3.14 M |
-$682,897.86 |
| Operating Expenses |
$87.69 M |
$64.28 M |
$88.00 M |
$53.19 M |
$53.92 M |
$47.69 M |
$54.13 M |
$33.94 M |
$29.45 M |
$19.29 M |
| Cost And Expenses |
$89.74 M |
$64.28 M |
$88.00 M |
$53.19 M |
$55.71 M |
$47.69 M |
$54.13 M |
$33.94 M |
$29.45 M |
$19.29 M |
| Interest Income |
$10.40 M |
$1.51 M |
$178,951.00 |
$4,000.00 |
$5,566.87 |
$3.66 M |
$4.38 M |
$9,999.63 |
$42,725.00 |
$76,841.00 |
| Interest Expense |
$16.46 M |
$4.40 M |
$281,000.00 |
$255,000.00 |
$41,751.00 |
$556,102.00 |
$1.65 M |
$1.08 M |
-$351,062.23 |
-$14,845.61 |
| Depreciation &
Amortization |
$2.05 M
|
$2.51 M
|
$2.46 M
|
$2.00 M
|
$1.79 M
|
$1.49 M
|
$348,205.00
|
$72,497.00
|
$68,361.00
|
$49,721.00
|
| EBITDA |
$1.00 M
|
-$52.63 M
|
-$62.74 M
|
-$37.13 M
|
-$21.56 M
|
$11.66 M
|
-$32.19 M
|
-$30.98 M
|
-$20.30 M
|
-$12.20 M
|
| EBITDA Ratio |
0 |
-86.33 |
-47.64 |
-59.85 |
-65.46 |
0.25 |
-0.37 |
-10.76 |
0 |
-8.54 |
| Operating Income Ratio
|
0
|
-102.36
|
-47.64
|
-61.85
|
-67.66
|
0.22
|
-0.51
|
-10.79
|
0
|
-8.44
|
| Total Other
Income/Expenses Net |
-$526.14 M
|
-$19.15 M
|
-$24.87 M
|
-$14.01 M
|
-$1.33 M
|
-$3.30 M
|
$1.91 M
|
-$854,000.00
|
$5.54 M
|
-$427,000.00
|
| Income Before Tax |
-$615.87 M |
-$78.78 M |
-$88.60 M |
-$52.91 M |
-$36.47 M |
$6.60 M |
-$15.42 M |
-$32.13 M |
-$28.69 M |
-$19.07 M |
| Income Before Tax Ratio
|
0
|
-111.86
|
-48.98
|
-61.52
|
-44.95
|
0.12
|
-0.43
|
-11.16
|
0
|
-8.41
|
| Income Tax Expense |
-$946,000.00 |
-$4.40 M |
-$2.46 M |
-$213,000.00 |
-$5.81 M |
-$3.27 M |
-$5.32 M |
-$5.42 M |
-$4.36 M |
-$1.95 M |
| Net Income |
-$614.93 M |
-$74.38 M |
-$86.15 M |
-$52.70 M |
-$30.66 M |
$9.87 M |
-$10.09 M |
-$26.71 M |
-$24.34 M |
-$17.12 M |
| Net Income Ratio |
0 |
-105.61 |
-47.62 |
-61.28 |
-37.79 |
0.17 |
-0.28 |
-9.28 |
0 |
-7.55 |
| EPS |
-0.99 |
-0.38 |
-0.93 |
-0.76 |
-0.19 |
0.11 |
-0.16 |
-0.43 |
-0.41 |
-0.43 |
| EPS Diluted |
-0.99 |
-0.38 |
-0.93 |
-0.76 |
-0.19 |
0.11 |
-0.15 |
-0.43 |
-0.41 |
-0.43 |
| Weighted Average Shares
Out |
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$164.15 M
|
$86.14 M
|
$65.03 M
|
$61.55 M
|
$59.10 M
|
$39.60 M
|
| Weighted Average Shares
Out Diluted |
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$164.15 M
|
$86.14 M
|
$65.43 M
|
$61.55 M
|
$59.10 M
|
$39.60 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
